Press Release Archive

 
08.07.2020 - Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced a multi-year agreement with G

 
08.06.2020 - Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that it will be holding its rescheduled Investor Day virtually over two days: Monday, September 14, 2020 from 1:00 p.m. EDT to approximately 4:00 p.m. EDT and Tuesday, September 15, 2020 from 10:00 a.m. EDT to approximately 1:00 p.m. EDT.

 
08.05.2020 - Pfizer and BioNTech to Supply Canada with their BNT162 mRNA- Based Vaccine Candidate
  • Supply to be provided over the course of 2021, subject to Health Canada approval
  • Agreement is part of Pfizer's and BioNTech's global commitment to help address the pandemic
  • Pfizer and BioNTech began a Phase 2b/3 safety and efficacy trial and remain on track to seek regulatory review as early as October 2020 , and manufacture globally up to 100 million dos
 
08.05.2020 - LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer
*/ /*-->*/ /*-->*/

Phase 3 CROWN trial meets primary endpoint at an interim analysis for efficacy

 
07.31.2020 - Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate
*/ /*-->*/ /*-->*/
  •  Supply of 120 million doses to be provided in the first half of 2021, subject to regulatory approval
  • Agreement is part of Pfizer’s and BioNTech’s global commitment to help address the pandemic
  • Pfizer and BioNTech began a Phase 2b/3 safety and
 
07.27.2020 - Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
*/ /*-->*/ /*-->*/
  • Companies advance nucleoside-modified messenger RNA (modRNA) candidate BNT162b2, which encodes an optimized SARS-CoV-2 full-length spike glycoprotein, at a 30µg dose level in a 2 dose regimen into Phase 2/3 Study
  • Candidate and dose level selection info
 
07.22.2020 - Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
*/ /*-->*/ /*-->*/
  • U.S. government placed an initial order of 100 million doses for $1.95 billion and can acquire up to 500 million additional doses
  • Americans to receive the vaccine for free consistent with U.S.
 
07.20.2020 - Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
*/ /*-->*/ /*-->*/
  • The data further demonstrated the ability of BNT162b1 to elicit high SARS-CoV-2 neutralizing titers
  • BNT162b1 elicited strong CD4+ and CD8+ T cell responses against SARS-CoV-2-rece
 
07.20.2020 - Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2
*/ /*-->*/ /*-->*/
  • Thirty million doses expected to be delivered in 2020 and 2021, subject to regulatory approval or authorization
  • Pfizer and BioNTech remain on track to begin an anticipated Phase 2b/3 safety and efficacy trial later this month, seek regulatory review as early as Oc
 
07.13.2020 - Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
*/ /*-->*/ /*-->*/

Anticipated large, global Phase 2b/3 safety and efficacy study may begin as early as July 2020

 
07.09.2020 -   Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance
*/ /*-->*/ /*-->*/
  • Funding to Support Development of New Antibiotics as Part of Broader Industry Effort
  • New Partnership with More than 20 Other Companies Will Focus on Medicines that Address Most Resistant Bacteria and Life-Threatening Infections
  • Builds on Pfizer’s longstanding work to address the global burden of infectious di
 
06.30.2020 - FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
  • First and only FDA-approved immunotherapy to demonstrate a significant overall survival benefit in the first-line setting in a Phase III study
  • In JAVELIN Bladder 100, BAVENCIO maintenance treatment extended median overall survival by 50% over standard of care
  • Priority review completed under FDA’s Real-Time Oncology Review (RTOR) pilot program, following receipt of Breakthrough Therapy Designation

Rockland, MA and New York, US, JUNE 30, 2020 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer In

 
06.30.2020 - European Commission Approves DAURISMO™ (glasdegib) for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

NEW YORK, N.Y., June 29, 2020 – Pfizer Inc. (NYSE:PFE) today announced that the European Commission approved DAURISMO™ (glasdegib), a Hedgehog pathway inhibitor, in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly diagnosed (de novo or secondary) acute myeloid leukemia (AML) in adult patients who are not candidates for standard chemotherapy.

 
06.25.2020 - Pfizer Declares Third-Quarter 2020 Dividend
*/ /*-->*/ /*-->*/

Board of Directors approves quarterly cash dividend of $0.38 per share

 
06.24.2020 - Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa
*/ /*-->*/ /*-->*/
  • Antimicrobial resistance is a leading global health challengei that requires urgent action to ensure a safer world for everyone, everywhere
  • Effective surveillance and timely data feedback are cri
 
06.22.2020 - European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Darmstadt, Germany, and New York, US, June 22, 2020 – Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency (EMA) has validated for review the Type II variation application for BAVENCIO® (avelumab) for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC). With this validation, the application is complete, and the EMA will now begin the review procedure.

 
06.22.2020 - Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines
*/ /*-->*/ /*-->*/

First subjects recently administered immunizations in two studies of 20-valent pneumococcal conjugate vaccine candidate in infants; a pentavalent meningococcal vaccine candidate in adolescents; and a respiratory syncytial virus vaccine candidate in

 
06.22.2020 - European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Notintendedfor UK-based media

Darmstadt, Germany, and New York, US, June 22, 2020 – Merck and Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency (EMA) has validated for review the Type II variation application for BAVENCIO® (avelumab) for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC). With this validation, the application is complete, and the EMA will now begin the review procedure.

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.